Time to cardiovascular death, myocardial infarction, or stroke, whichever occurs first

Time to death by any cause [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]

Time to death by any cause

Time to cardiovascular death or hospitalization for worsening heart failure [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]

Time to cardiovascular death or hospitalization for worsening heart failure, whichever occurs first

Time to ischemic fatal or non-fatal stroke or TIA [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]

Time to ischemic fatal or non-fatal stroke or TIA, whichever occurs first

Current Other Outcome Measures ICMJE

Not Provided

Original Other Outcome Measures ICMJE

Not Provided

Descriptive Information

Brief Title ICMJE

Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

Official Title ICMJE

A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Additional LDL-Cholesterol Reduction on Major Cardiovascular Events When Evolocumab (AMG 145) is Used in Combination With Statin Therapy In Patients With Clinically Evident Cardiovascular Disease

Brief Summary

The primary hypothesis is that additional LDL-C lowering with Evolocumab (AMG 145) when used in addition to other treatment for dyslipidemia is well tolerated and decreases the risk of cardiovascular death, myocardial infarction, hospitalization for unstable angina, stroke, or coronary revascularization in subjects with clinically evident cardiovascular disease.